For General Information, page-215

Referring to "The Company has also made an application to a government investment program for funding of the clinical trial and will advise the market should its application be successful."

I think ANP applied for Medical Research Future fund as mentioned earlier by CrispyPork777. (The Medical research fund is a $20 billion long-term investment supporting Australian health and medical research. The MRFF aims to transform health and medical research and innovation to improve lives, build the economy and contribute to health system sustainability.)

https://www.health.gov.au/initiatives-and-programs/medical-research-future-fund





Description: Applications to this grant opportunity must propose research that addresses one of the six Streams of research. An application may be submitted to one of the six Streams only.

I just refer to only stream 1 - Conduct a clinical trial of new drug and/or non-drug treatments and therapies for rare cancers, rare diseases and/or unmet needs.

Individual grant applications must not exceed a budget of $3m

As for Australian Government's BTB grant program that PXS applied in 2020, the successful applicant can only receive up to $1m of matching fund over a period of up to 2 years.

I'm not so sure anyone here aware of this, Pharmaxis has discontinued their DMD program. Reason: The preclinical compound didn't achieve the expected outcome, and the indication is not being further pursued.

ANP is the only biotech ASX company that progress in treatment for DMD as far as i know.